We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DCN Diagnostics and Asahi Kasei Fibers Launch Market Collaboration

By LabMedica International staff writers
Posted on 30 Jul 2013
DCN Diagnostics (Carlsbad, CA, USA) and Asahi Kasei Fibers Corp. (AKFC; Osaka, Japan) will collaborate on a new colored nanoparticle designed to increase sensitivity in rapid assays. The new partnership will be based around AKFC's patented high-performance cellulose nanobead product, NanoAct. NanoAct represents a major step forward in visual labels for use in lateral flow and other rapid assays.

Utilizing cellulose technology matured and advanced for more than 80 years, Asahi Kasei developed patented and innovative colored nanobeads, NanoAct. Using the multicolored nanobeads as labels for lateral flow immunoassays, increased sensitivity, and faster test time is expected. NanoAct also has dispersion stability and does not require surfactants for aggregation control.

Consisting of a range of high intensity colored beads NanoAct can be multiplexed, generate higher sensitivity, lower CV's, and improved stability over many existing visual labels such as colloidal gold. This enables the application of lateral flow assays in demanding field assays for emerging infectious disease, consumer applications, biothreat detection, and biomarker testing.

DCN is a supplier of assay development, training, and consulting services to lateral flow assay developers and manufacturers. The company will be AKFC's distribution partner in North America and will be their preferred provider of Original Equipment Manufacturer (OEM) services to NanoAct users worldwide, except Japan.

"This new product line is a great addition to DCN's existing portfolio of high performance reagents and materials for lateral flow test producers," said DCN's president, Brendan O'Farrell. "This new product line is a great addition to DCN's existing portfolio of high performance reagents and materials for lateral flow test producers."

DCN and AKFC will be showcasing NanoAct at the AACC conference in Houston, Texas (USA), on July 28–August 1, 2013.

Related Links:

DCN Diagnostics
Asahi Kasei Fibers Corp.




New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Tabletop Centrifuge
Mikro 185
New
Urine Strips
11 Parameter Urine Strips

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests